Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Daftarian, Pirouz M ^a,b   Mansour, Marc ^a   Pohajdak, Bill ^a   Fuentes Ortega, Antar ^a   Korets Smith, Ella ^a   MacDonald, Lisa ^a   Weir, Genevieve ^a   Brown, Robert G ^a   Kast, W Martin ^c  

^a ImmunoVaccine Technologies Inc   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VACCIMAX; CYTOKINE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LINE; CELL MEDIATED CYTOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMULSION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN PAPILLOMAVIRUS TYPE 16; MONOTHERAPY; MOUSE; NONHUMAN; PROVOCATION TEST; SINGLE DRUG DOSE; TRANSGENIC MOUSE; AGING; ANIMAL; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; INSTRUMENTATION; INTRACELLULAR SPACE; METABOLISM; NEOPLASM; PATHOLOGY; SPLEEN; STAINING; TUMOR CELL LINE;

AGING; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; INTRACELLULAR SPACE; MICE; NEOPLASMS; PEPTIDES; SPLEEN; STAINING AND LABELING; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34447265731     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-26     Document Type: Article

References (16)

1. Gravekamp C Tailoring cancer vaccines to the elderly: The importance of suitable mouse models Mech Ageing Dev 2001 122 11 1087-1105 10.1016/ S0047-6374(01)00252-4 11389926
2. Pawelec G Immunosenescence and vaccination Immun Ageing 2005 2 16 1315345 16307681 10.1186/1742-4933-2-16
3. Provinciali M Argentati K Tibaldi A Efficacy of cancer gene therapy in aging: Adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice Gene Ther 2000 7 7 624-632 10.1038/sj.gt.3301131 10819579
4. Keitel WA Atmar RL Cate TR Petersen NJ Greenberg SB Ruben F Couch RB Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons Arch Intern Med 2006 166 10 1121-1127 10.1001/archinte.166.10.1121 16717175
5. McElhaney JE Nichol KL Influenza vaccines: Crossing the translational gap to improve outcomes in the elderly Aging Health 2005 1 1 167-177 10.2217/1745509X.1.1.167
6. Daftarian P Mansour M Benoit AC Pohajdak B Hoskin DW Brown RG Kast WM Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine 2006 24 24 5235-5244 10.1016/j.vaccine.2006.03.079 16675074
7. Feltkamp MC Smits HL Vierboom MP Minnaar RP de Jongh BM Drijfhout JW ter Schegget J Melief CJ Kast WM Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol 1993 23 9 2242-2249 10.1002/eji.1830230929 7690326
8. Lin KY Guarnieri FG Staveley-O'Carroll KF Levitsky HI August JT Pardoll DM Wu TC Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen Cancer Res 1996 56 1 21-26 8548765
9. Peng S Trimble C He L Tsai YC Lin CT Boyd DA Pardoll D Hung CF Wu TC Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice Gene Ther 2006 13 1 67-77 10.1038/sj.gt.3302607 16107858
10. Ressing ME Sette A Brandt RM Ruppert J Wentworth PA Hartman M Oseroff C Grey HM Melief CJ Kast WM Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J Immunol 1995 154 11 5934-5943 7538538
11. Velders MP Weijzen S Eiben GL Elmishad AG Kloetzel PM Higgins T Ciccarelli RB Evans M Man S Smith L Kast WM Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol 2001 166 9 5366-5373 11313372
12. Cassetti MC McElhiney SP Shahabi V Pullen JK Le Poole IC Eiben GL Smith LR Kast WM Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine 2004 22 3-4 520-527 10.1016/j.vaccine.2003.07.003 14670335
13. Eiben GL Velders MP Schreiber H Cassetti MC Pullen JK Smith LR Kast WM Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res 2002 62 20 5792-5799 12384540
14. Engelhard VH Lacy E Ridge JP Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein J Immunol 1991 146 4 1226-1232 1704033
15. Shirai M Arichi T Nishioka M Nomura T Ikeda K Kawanishi K Engelhard VH Feinstone SM Berzofsky JA CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1 J Immunol 1995 154 6 2733-2742 7533182
16. Sanders GD Taira AV Cost-effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 2003 9 1 37-48 12533280